MENU

REPL Stock Replimune Group (REPL, $10.32) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 3, 2025

A.I.dvisor
at Tickeron.com
Loading...
REPL - Replimune Group
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $10.32
Daily change: +$0.32 (+3.2%)
Daily volume: 2M
Capitalization: $809.5M
Industry: Biotechnology

This is a Bullish indicator signaling REPL's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 52 similar cases where REPL's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

Aroon Indicator for REPL shows an upward move is likely

REPL's Aroon Indicator triggered a bullish signal on December 11, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 190 similar instances where the Aroon Indicator showed a similar pattern. In of the 190 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for REPL moved above the 200-day moving average on December 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for REPL moved out of overbought territory on December 09, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where REPL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on December 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on December 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

REPL broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.032) is normal, around the industry mean (28.362). P/E Ratio (0.000) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (336.196).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
REPL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. REPL showed earnings on November 06, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of oncolytic immunotherapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
284
Web
https://www.replimune.com